ClinicalTrials.gg
CompletedNCT01112462Updated Jul 10, 2012

To Test Bioequivalence Between Two Formulations of Paracetamol/Phenylephrine

A Phase 1 interventional study of Paracetamol 500 mg/Phenylephrine 5 mg tablets and Paracetamol 1000 mg/Phenylephrine 10 mg sachet in Respiratory Tract Infections, sponsored by McNeil AB. Completed at 1 site in Ireland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-10.

Sponsored by McNeil AB (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Respiratory Tract Infections by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Respiratory Tract Infections · Johnson & Johnson.

Started
2010
the only one that year
Phase 1
2 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Respiratory Tract Infections by Johnson & Johnson, this one is the only one that started in 2010, is one of 2 in phase 1, and was the 5th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 113 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 10 studies in Respiratory Tract Infections by Johnson & Johnson is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 34 (46%) set no upper age limit and 32 (43%) stop at 75 or younger; 34 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Respiratory Tract Infections by Johnson & Johnson as a file.
02

Study summary

This study is designed to assess bioequivalence between two paracetamol/ phenylephrine combination products.

Read the detailed description

The study will be a single dose, randomized, two-way crossover study in 40 healthy subjects, with equal numbers of males and females. Drop-outs will not be replaced. The two doses of medication given in the study (a single dose in each of the two study periods) will be separated by a washout period of at least 7 days. In each study period, sixteen blood samples for pharmacokinetic analysis will be taken over 24 hours. Blood samples will be centrifuged and concentrations of paracetamol and phenylephrine in plasma will be measured using a validated chromatographic assay. Pharmacokinetic parameters will be calculated from plasma concentration data. The rate and extent of absorption of the formulations will be compared.

03

Conditions studied

  • Respiratory Tract Infections

Keywords

  • Nasal congestion, Headache
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female
  • Caucasians
  • Aged between 18 and 50 years
  • ≤ 30 kg/m2
  • Clinically normal medical history
  • Physical normal examination
  • Normal laboratory test results

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, lactation or intended pregnancy
  • to or intolerant of the study medications
  • Donation or loss of blood within 90 days preceding the first dose of study medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Tablet

    Paracetamol 500 mg/Phenylephrine 5 mg tablet

    Drug: Paracetamol 500 mg/Phenylephrine 5 mg tablets

  • Active comparator
    Sachet

    Paracetamol 1000 mg/Phenylephrine 10 mg sachet

    Drug: Paracetamol 1000 mg/Phenylephrine 10 mg sachet

Interventions

  • DrugParacetamol 500 mg/Phenylephrine 5 mg tablets

    Drug page: Acetaminophen

    2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period

    Also known as: Sudafed PE Sinus Pain Relief™

  • DrugParacetamol 1000 mg/Phenylephrine 10 mg sachet

    Drug page: Acetaminophen

    1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period

    Also known as: Flu Plus Hot Lemon™ sachet

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic measurements

    Pharmacokinetic measurements including: * Cmax (Maximum concentration) * AUC0-t (Area under the plasma concentration versus time curve from 0h to the lastmeasurable concentration) * AUC0-inf (Area under the plasma concentration versus time curve from 0h to infinity)

    Time frame: during 24 hours following drug administration

07

Study locations

1 site
  • Shandon Clinical Trials Ltd.
    Cork, Ireland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2010
First posted
Apr 28, 2010
Start
Mar 2010
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Last update
Jul 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01112462
Lead sponsor
McNeil AB
Responsible party
Sponsor
First posted
Apr 28, 2010
Start date
Mar 2010
Primary completion
Jun 2010
Completion
Jun 2010
Last update
Jul 10, 2012

Study contacts

Elisabeth Kruse, PhD
study director · McNeil AB

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion